Fintel reports that on September 5, 2025, Truist Securities initiated coverage of Revolution Medicines (NasdaqGS:RVMD) with a Buy recommendation.

Analyst Price Forecast Suggests 90.05% Upside

As of September 2, 2025, the average one-year price target for Revolution Medicines is $74.02/share. The forecasts range from a low of $56.56 to a high of $92.40. The average price target represents an increase of 90.05% from its latest reported closing price of $38.95 / share.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Revolution Medicines is 19MM, an increase of 2,481.00%. The projected annual non-GAAP EPS is -3.46.

What is the Fund Sentiment?

There are 688 funds or institutions reporting positions in Revolution Medicines. This is an increase of 33 owner(s) or 5.04% in the last quarter. Average portfolio weight of all funds dedicated to RVMD is 0.49%, an increase of 27.69%. Total shares owned by institutions decreased in the last three months by 7.63% to 209,830K shares. The put/call ratio of RVMD is 0.35, indicating a bullish outlook.

What are Other Shareholders Doing?

Farallon Capital Management holds 14,326K shares representing 7.66% ownership of the company. In its prior filing, the firm reported owning 13,535K shares , representing an increase of 5.52%. The firm decreased its portfolio allocation in RVMD by 14.78% over the last quarter.

Janus Henderson Group holds 10,591K shares representing 5.67% ownership of the company. In its prior filing, the firm reported owning 10,190K shares , representing an increase of 3.78%. The firm decreased its portfolio allocation in RVMD by 68.88% over the last quarter.

Wellington Management Group Llp holds 10,260K shares representing 5.49% ownership of the company. In its prior filing, the firm reported owning 11,788K shares , representing a decrease of 14.89%. The firm decreased its portfolio allocation in RVMD by 88.01% over the last quarter.

Baker Bros. Advisors holds 9,365K shares representing 5.01% ownership of the company. In its prior filing, the firm reported owning 7,937K shares , representing an increase of 15.25%. The firm increased its portfolio allocation in RVMD by 7.62% over the last quarter.

Nextech Invest holds 7,601K shares representing 4.07% ownership of the company. No change in the last quarter.